bioRxivImmunologyPreprint
Indoleamine 2,3-dioxygenase-1 expressing aggregate bone marrow dendritic cell populations are associated with systemic T cell compartment changes in chronic myelomonocytic leukemia
A. Mangaonkar, K. K. Reichard, M. Binder, G. Coltro, T. L. Lasho, R. M. Carr, A. Chiu, V. Negron, M. Hefazi, T. Anagnostou, J. C. Villasboas, W. Gonsalves, N. Gangat, M. Shah, H. B. Alkhateeb, A. Al-Kali, M. A. Elliott, K. H. Begna, A. P. Wolanskyj-Spinner, M. R. Litzow, W. J. Hogan, S. M. Ansell, A. Pardanani, A. Tefferi, M. M. Patnaik
Abstract
Systemic immune tolerance is not well-characterized in chronic myelomonocytic leukemia (CMML). Due to the presence of clonal plasmacytoid dendritic cells (pDC) in CMML, and the established association of lymph node indoleamine 2,3-dioxygenase-1 (IDO1)-positive (+) DC populations (IDC) with systemic immune tolerance in other malignant contexts, we sought to determine the association of IDO1 expression and bone marrow (BM) DC populations with systemic T-cell compartment changes using primary CMML patient samples (BM, plasma, and peripheral blood mononuclear cells) via immunohistochemistry (IHC), liquid chromatography-mass spectrometry (LC-MS), and time-of-flight mass cytometry (CyTOF). Our results highlight that aggregate BM IDC (CD123 and/or CD11c positive) occur in 33% CMML patients at any disease time-point (IHC), correlate with accentuated tryptophan catabolism (LC-MS, increased kynurenine level, median 4.7 versus 3 microM, P=0.049*), systemic regulatory T-cell expansion (CyTOF, %parent cell type, 14.5 versus 4.9%, P=0.04*) and play a role in disease progression, as evidenced by a higher rate of transformation to acute myeloid leukemia (41 versus 13%, P=0.002**), when compared to CMML patients without BM IDC. Our data also highlight a perturbed immune system in CMML with specific systemic immune signatures, particularly type 1, IL-17 producing helper T, CD4 terminal effector and natural killer cell suppression. Key PointsO_LIAggregate IDO1+ dendritic cell populations occur in the CMML bone marrow microenvironment, and their presence correlates with disease progression. C_LIO_LISystemic immune microenvironment signatures in CMML indicate an altered T- and natural killer (NK)-cell balance. Specifically, suppression of type 1 helper T (Th1), IL-17 producing helper T (Th17), CD4 terminal effector and NK cells. C_LIO_LIIDO1+ bone marrow dendritic cell populations in CMML are associated with a T-cell compartment shift towards a regulatory T cell phenotype. C_LI
- organism: human
- assay: flow cytometry
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency
P. A. Flynn, M. D. Long, … E. F. Lind·bioRxiv·Sep 19, 2023
- A Circulating TLR2pos CD14neg CD16neg '' Unclassified Subset '' is Decreased in Multiple Myeloma Patients and May Comprise CD163pos Dendritic Cells.
Mie Wolff Kristensen, Sarah Lindhøj Kvorning, … Morten Nørgaard Andersen·bioRxiv·Jul 25, 2026
- Hallmarks of tumor-experienced T cells are absent in multiple myeloma patients from diagnosis through maintenance therapy
Carolyn Shasha, David Richard Glass, … Evan William Newell·BloodPeer-reviewed·Mar 31, 2025
- High-Dimensional Spatiotemporal Single-Cell and 3D Atlas of the Bone Marrow Microenvironment during Leukemic Progression
Lan‐Zhu Li, Isabelle Rottmann, … Christian M. Schürch·bioRxiv·Sep 27, 2025
- Dysregulated lymphocyte localization in idiopathic multicentric Castleman disease
Melanie D. Mumau, Michael V. Gonzalez, … David C. Fajgenbaum·bioRxiv·Dec 15, 2025
- Scalable generation of pure CD103⁺ cDC1 from iDC1 cultures
S.K. Sharma, Fiona Flynn, … Christian T. Mayer·bioRxiv·Jan 1, 2026